Borges, B., Canepa, E., Chang, I. J., Herzeg, A., Lianoglou, B., Kishnani, P. S., Harmatz, P., MacKenzie, T. C., & Cohen, J. L. (2025). Prenatal Delivery of Enzyme Replacement Therapy to Fetuses Affected by Early-Onset Lysosomal Storage Diseases. American journal of medical genetics. Part C, Seminars in medical genetics, e32132. Advance online publication. https://doi.org/10.1002/ajmg.c.32132
Koeberl DD, Koch RL, Lim J, Brooks ED, Arnson BD, Sun B, Kishnani PS. Gene therapy for glycogen storage diseases. Journal of Inherited Metabolic Disease. 2023 Jul 8. doi: 10.1002/jimd.12654. PMID: 37421310 PMCID: PMC10874648.
Arnson, B., Ilich, E., von Beck, T., Li, S., Brooks, E. D., Gheorghiu, D., He, G., Weinrub, M., Chan, S. Y., Kang, H. R., Courtney, D., Everitt, J., Cullen, B. R., & Koeberl, D. D. (2025). Efficacious genome editing in infant mice with glycogen storage disease type Ia. JCI insight, e181760. Advance online publication. https://doi.org/10.1172/jci.insight.181760
Arnson, B., Kang, H. R., Brooks, E. D., Gheorghiu, D., Ilich, E., Courtney, D., Everitt, J. I., Cullen, B. R., & Koeberl, D. D. (2023). Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia. Molecular therapy. Methods & clinical development, 29, 108–119. https://doi.org/10.1016/j.omtm.2023.03.001
Yavarow, Z. A., Kang, H. R., Waskowicz, L. R., Bay, B. H., Young, S. P., Yen, P. M., & Koeberl, D. D. (2020). Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. Human molecular genetics, 29(2), 286–294. https://doi.org/10.1093/hmg/ddz290
Kang, H. R., Gjorgjieva, M., Smith, S. N., Brooks, E. D., Chen, Z., Burgess, S. M., Chandler, R. J., Waskowicz, L. R., Grady, K. M., Li, S., Mithieux, G., Venditti, C. P., Rajas, F., & Koeberl, D. D. (2019). Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease. Molecular therapy. Methods & clinical development, 15, 383–391. https://doi.org/10.1016/j.omtm.2019.10.016
Kang, H. R., Waskowicz, L., Seifts, A. M., Landau, D. J., Young, S. P., & Koeberl, D. D. (2019). Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia. Molecular therapy. Methods & clinical development, 13, 265–273. https://doi.org/10.1016/j.omtm.2019.02.002
Waskowicz, L. R., Zhou, J., Landau, D. J., Brooks, E. D., Lim, A., Yavarow, Z. A., Kudo, T., Zhang, H., Wu, Y., Grant, S., Young, S. P., Huat, B. B., Yen, P. M., & Koeberl, D. D. (2019). Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. Human molecular genetics, 28(1), 143–154. https://doi.org/10.1093/hmg/ddy343
Zhou, J., Waskowicz, L. R., Lim, A., Liao, X. H., Lian, B., Masamune, H., Refetoff, S., Tran, B., Koeberl, D. D., & Yen, P. M. (2019). A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. Thyroid : official journal of the American Thyroid Association, 29(8), 1158–1167. https://doi.org/10.1089/thy.2019.0007
Brooks, E. D., Landau, D. J., Everitt, J. I., Brown, T. T., Grady, K. M., Waskowicz, L., Bass, C. R., D'Angelo, J., Asfaw, Y. G., Williams, K., Kishnani, P. S., & Koeberl, D. D. (2018). Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy. Journal of inherited metabolic disease, 41(6), 965–976. https://doi.org/10.1007/s10545-018-0223-y
Farah, B. L., Landau, D. J., Wu, Y., Sinha, R. A., Loh, A., Bay, B. H., Koeberl, D. D., & Yen, P. M. (2017). Renal endoplasmic reticulum stress is coupled to impaired autophagy in a mouse model of GSD Ia. Molecular genetics and metabolism, 122(3), 95–98. https://doi.org/10.1016/j.ymgme.2017.08.013
Farah, B. L., Landau, D. J., Sinha, R. A., Brooks, E. D., Wu, Y., Fung, S. Y. S., Tanaka, T., Hirayama, M., Bay, B. H., Koeberl, D. D., & Yen, P. M. (2016). Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency. Journal of hepatology, 64(2), 370–379. https://doi.org/10.1016/j.jhep.2015.10.008
Kishnani, P. S., Austin, S. L., Abdenur, J. E., Arn, P., Bali, D. S., Boney, A., Chung, W. K., Dagli, A. I., Dale, D., Koeberl, D., Somers, M. J., Wechsler, S. B., Weinstein, D. A., Wolfsdorf, J. I., Watson, M. S., & American College of Medical Genetics and Genomics (2014). Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genetics in medicine : official journal of the American College of Medical Genetics, 16(11), e1. https://doi.org/10.1038/gim.2014.128
Brooks, E. D., Little, D., Arumugam, R., Sun, B., Curtis, S., Demaster, A., Maranzano, M., Jackson, M. W., Kishnani, P., Freemark, M. S., & Koeberl, D. D. (2013). Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia. Molecular genetics and metabolism, 109(2), 161–170. https://doi.org/10.1016/j.ymgme.2013.03.018
Demaster, A., Luo, X., Curtis, S., Williams, K. D., Landau, D. J., Drake, E. J., Kozink, D. M., Bird, A., Crane, B., Sun, F., Pinto, C. R., Brown, T. T., Kemper, A. R., & Koeberl, D. D. (2012). Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. Human gene therapy, 23(4), 407–418. https://doi.org/10.1089/hum.2011.106
Koeberl, D. D., Koch, R. L., Lim, J. A., Brooks, E. D., Arnson, B. D., Sun, B., & Kishnani, P. S. (2024). Gene therapy for glycogen storage diseases. Journal of inherited metabolic disease, 47(1), 93–118. https://doi.org/10.1002/jimd.12654
Choi, S. J., Yi, J. S., Lim, J. A., Tedder, T. F., Koeberl, D. D., Jeck, W., Desai, A. K., Rosenberg, A., Sun, B., & Kishnani, P. S. (2023). Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease. The journal of gene medicine, 25(8), e3509. https://doi.org/10.1002/jgm.3509
Hannah, W. B., Case, L. E., Smith, E. C., Walters, C., Bali, D., Kishnani, P. S., & Koeberl, D. D. (2023). Screening data from 19 patients with late-onset Pompe disease for a phase I clinical trial of AAV8 vector-mediated gene therapy. JIMD reports, 64(5), 393–400. https://doi.org/10.1002/jmd2.12391
Smith, E. C., Hopkins, S., Case, L. E., Xu, M., Walters, C., Dearmey, S., Han, S. O., Spears, T. G., Chichester, J. A., Bossen, E. H., Hornik, C. P., Cohen, J. L., Bali, D., Kishnani, P. S., & Koeberl, D. D. (2023). Phase I study of liver depot gene therapy in late-onset Pompe disease. Molecular therapy : the journal of the American Society of Gene Therapy, 31(7), 1994–2004. https://doi.org/10.1016/j.ymthe.2023.02.014
Kishnani, P. S., & Koeberl, D. D. (2019). Liver depot gene therapy for Pompe disease. Annals of translational medicine, 7(13), 288. https://doi.org/10.21037/atm.2019.05.02
Lim, J. A., Yi, H., Gao, F., Raben, N., Kishnani, P. S., & Sun, B. (2019). Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease. Molecular therapy. Methods & clinical development, 12, 233–245. https://doi.org/10.1016/j.omtm.2019.01.006
Li, S., Sun, B., Nilsson, M. I., Bird, A., Tarnopolsky, M. A., Thurberg, B. L., Bali, D., & Koeberl, D. D. (2013). Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 27(1), 34–44. https://doi.org/10.1096/fj.12-207472
Luo, X., Hall, G., Li, S., Bird, A., Lavin, P. J., Winn, M. P., Kemper, A. R., Brown, T. T., & Koeberl, D. D. (2011). Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Molecular therapy : the journal of the American Society of Gene Therapy, 19(11), 1961–1970. https://doi.org/10.1038/mt.2011.126
Sun, B., Li, S., Bird, A., & Koeberl, D. D. (2010). Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. Gene therapy, 17(12), 1500–1505. https://doi.org/10.1038/gt.2010.109
Sun, B., Young, S. P., Li, P., Di, C., Brown, T., Salva, M. Z., Li, S., Bird, A., Yan, Z., Auten, R., Hauschka, S. D., & Koeberl, D. D. (2008). Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Molecular therapy : the journal of the American Society of Gene Therapy, 16(8), 1366–1371. https://doi.org/10.1038/mt.2008.133
Sun, B., Zhang, H., Benjamin, D. K., Jr, Brown, T., Bird, A., Young, S. P., McVie-Wylie, A., Chen, Y. T., & Koeberl, D. D. (2006). Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Molecular therapy : the journal of the American Society of Gene Therapy, 14(6), 822–830. https://doi.org/10.1016/j.ymthe.2006.08.001
Sun, B., Zhang, H., Franco, L. M., Brown, T., Bird, A., Schneider, A., & Koeberl, D. D. (2005). Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Molecular therapy : the journal of the American Society of Gene Therapy, 11(6), 889–898. https://doi.org/10.1016/j.ymthe.2005.01.012
Kushlaf, H., Díaz-Manera, J., Bratkovic, D., Byrne, B. J., Claeys, K. G., Clemens, P. R., Dimachkie, M. M., Kishnani, P. S., Laforêt, P., Roberts, M., Schoser, B., Toscano, A., Castelli, J., Holdbrook, F., Sitaraman Das, S., Goldman, M., Mozaffar, T., & PROPEL Study Group (2025). Switching Enzyme Replacement Therapy for Late-Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL. Muscle & nerve, 72(2), 230–239. https://doi.org/10.1002/mus.28420
Kishnani, P. S., Chien, Y. H., Berger, K. I., Thibault, N., & Sparks, S. (2024). Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease. Molecular genetics and metabolism, 143(1-2), 108559. https://doi.org/10.1016/j.ymgme.2024.108559
Desai, A. K., Smith, P. B., Yi, J. S., Rosenberg, A. S., Burt, T. D., & Kishnani, P. S. (2024). Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease. Frontiers in immunology, 14, 1301912. https://doi.org/10.3389/fimmu.2023.1301912
Kishnani, P. S., Kronn, D., Brassier, A., Broomfield, A., Davison, J., Hahn, S. H., Kumada, S., Labarthe, F., Ohki, H., Pichard, S., Prakalapakorn, S. G., Haack, K. A., Kittner, B., Meng, X., Sparks, S., Wilson, C., Zaher, A., Chien, Y. H., & Mini-COMET Investigators (2023). Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary analysis report. Genetics in medicine : official journal of the American College of Medical Genetics, 25(2), 100328. https://doi.org/10.1016/j.gim.2022.10.010
Herzeg, A., Borges, B., Lianoglou, B. R., Gonzalez-Velez, J., Canepa, E., Munar, D., Young, S. P., Bali, D., Gelb, M. H., Chakraborty, P., Kishnani, P. S., Harmatz, P., Cohen, J. L., & MacKenzie, T. C. (2023). Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects. Prenatal diagnosis, 43(13), 1638–1649. https://doi.org/10.1002/pd.6460
Cohen, J. L., Chakraborty, P., Fung-Kee-Fung, K., Schwab, M. E., Bali, D., Young, S. P., Gelb, M. H., Khaledi, H., DiBattista, A., Smallshaw, S., Moretti, F., Wong, D., Lacroix, C., El Demellawy, D., Strickland, K. C., Lougheed, J., Moon-Grady, A., Lianoglou, B. R., Harmatz, P., Kishnani, P. S., … MacKenzie, T. C. (2022). In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease. The New England journal of medicine, 387(23), 2150–2158. https://doi.org/10.1056/NEJMoa2200587
Diaz-Manera, J., Kishnani, P. S., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, V., Toscano, A., van der Ploeg, A. T., Berger, K. I., Clemens, P. R., Chien, Y. H., Day, J. W., Illarioshkin, S., Roberts, M., Attarian, S., Borges, J. L., Bouhour, F., Choi, Y. C., Erdem-Ozdamar, S., Goker-Alpan, O., … COMET Investigator Group (2021). Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. The Lancet. Neurology, 20(12), 1012–1026. https://doi.org/10.1016/S1474-4422(21)00241-6
McCall, A. L., Dhindsa, J. S., Bailey, A. M., Pucci, L. A., Strickland, L. M., & ElMallah, M. K. (2021). Glycogen accumulation in smooth muscle of a Pompe disease mouse model. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi, 57(0), 8–18. https://doi.org/10.1540/jsmr.57.8
Koeberl, D. D., Case, L. E., Smith, E. C., Walters, C., Han, S. O., Li, Y., Chen, W., Hornik, C. P., Huffman, K. M., Kraus, W. E., Thurberg, B. L., Corcoran, D. L., Bali, D., Bursac, N., & Kishnani, P. S. (2018). Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease. Molecular therapy : the journal of the American Society of Gene Therapy, 26(9), 2304–2314. https://doi.org/10.1016/j.ymthe.2018.06.023
Yi, H., Sun, T., Armstrong, D., Borneman, S., Yang, C., Austin, S., Kishnani, P. S., & Sun, B. (2017). Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. Journal of molecular medicine (Berlin, Germany), 95(5), 513–521. https://doi.org/10.1007/s00109-017-1505-9
Han, S. O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., & Koeberl, D. (2017). Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction. Molecular therapy. Methods & clinical development, 4, 126–136. https://doi.org/10.1016/j.omtm.2016.12.010
Lim, H. H., Yi, H., Kishimoto, T. K., Gao, F., Sun, B., & Kishnani, P. S. (2017). A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease. Molecular genetics and metabolism reports, 13, 18–22. https://doi.org/10.1016/j.ymgmr.2017.03.005
Kishnani, P. S., & Beckemeyer, A. A. (2014). New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatric endocrinology reviews : PER, 12 Suppl 1, 114–124.
Sun, B., Banugaria, S. G., Prater, S. N., Patel, T. T., Fredrickson, K., Ringler, D. J., de Fougerolles, A., Rosenberg, A. S., Waldmann, H., & Kishnani, P. S. (2014). Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Molecular genetics and metabolism reports, 1, 446–450. https://doi.org/10.1016/j.ymgmr.2014.08.005
Koeberl, D. D., Li, S., Dai, J., Thurberg, B. L., Bali, D., & Kishnani, P. S. (2012). β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Molecular genetics and metabolism, 105(2), 221–227. https://doi.org/10.1016/j.ymgme.2011.11.005
Zhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X. Y., Luo, X., Kemper, A. R., Clay, T. M., & Koeberl, D. D. (2012). Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Human gene therapy, 23(5), 460–472. https://doi.org/10.1089/hum.2011.063
Sun, B., Kulis, M. D., Young, S. P., Hobeika, A. C., Li, S., Bird, A., Zhang, H., Li, Y., Clay, T. M., Burks, W., Kishnani, P. S., & Koeberl, D. D. (2010). Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Molecular therapy : the journal of the American Society of Gene Therapy, 18(2), 353–360. https://doi.org/10.1038/mt.2009.195
Sun, B., Bird, A., Young, S. P., Kishnani, P. S., Chen, Y. T., & Koeberl, D. D. (2007). Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. American journal of human genetics, 81(5), 1042–1049. https://doi.org/10.1086/522236
Liao K-A, Han S-o, Barzi M, Yi H, Eisner W, Bissig-Choisat B, Bissig K-D, Sun B, High potency MyoAAV capsids enhanced skeletal muscle correction in a mouse model of GSD IIIa, Molecular Therapy - Methods & Clinical Development (2025), doi: https://doi.org/10.1016/j.omtm.2025.101567.
Liao KA, Lim JA, Choi SJ, Yi H, Sun B. Long-term correction of murine glycogen storage disease type III by AAV-mediated gene therapy using an immunotolerizing dual promoter to express bacterial pullulanase. Adv Cell Gene Ther. 2025 Apr. doi: 10.1155/acg2/4639392.
Lim, J. A., Kishnani, P. S., & Sun, B. (2022). Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice. JCI insight, 7(23), e152970. https://doi.org/10.1172/jci.insight.152970
Lim, J. A., Choi, S. J., Gao, F., Kishnani, P. S., & Sun, B. (2020). A Novel Gene Therapy Approach for GSD III Using an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme. Molecular therapy. Methods & clinical development, 18, 240–249. https://doi.org/10.1016/j.omtm.2020.05.034
Brooks, E. D., Yi, H., Austin, S. L., Thurberg, B. L., Young, S. P., Fyfe, J. C., Kishnani, P. S., & Sun, B. (2016). Natural Progression of Canine Glycogen Storage Disease Type IIIa. Comparative medicine, 66(1), 41–51.
Yi, H., Brooks, E. D., Thurberg, B. L., Fyfe, J. C., Kishnani, P. S., & Sun, B. (2014). Correction of glycogen storage disease type III with rapamycin in a canine model. Journal of molecular medicine (Berlin, Germany), 92(6), 641–650. https://doi.org/10.1007/s00109-014-1127-4
Sun, B., Fredrickson, K., Austin, S., Tolun, A. A., Thurberg, B. L., Kraus, W. E., Bali, D., Chen, Y. T., & Kishnani, P. S. (2013). Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for glycogen storage disease type III. Molecular genetics and metabolism, 108(2), 145–147. https://doi.org/10.1016/j.ymgme.2012.12.002
Yi, H., Thurberg, B. L., Curtis, S., Austin, S., Fyfe, J., Koeberl, D. D., Kishnani, P. S., & Sun, B. (2012). Characterization of a canine model of glycogen storage disease type IIIa. Disease models & mechanisms, 5(6), 804–811. https://doi.org/10.1242/dmm.009712
Kiely, B. T., Koch, R. L., Flores, L., Burner, D., Kaplan, S., & Kishnani, P. S. (2022). A novel approach to characterize phenotypic variation in GSD IV: Reconceptualizing the clinical continuum. Frontiers in genetics, 13, 992406. https://doi.org/10.3389/fgene.2022.992406
Hahn, S. H., Kronn, D., Leslie, N. D., Pena, L. D. M., Tanpaiboon, P., Gambello, M. J., Gibson, J. B., Hillman, R., Stockton, D. W., Day, J. W., Wang, R. Y., An Haack, K., Shafi, R., Sparks, S., Zhao, Y., Wilson, C., Kishnani, P. S., & Pompe ADVANCE Study Consortium (2018). Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. Genetics in medicine : official journal of the American College of Medical Genetics, 20(10), 1284–1294. https://doi.org/10.1038/gim.2018.2
Yi, H., Zhang, Q., Brooks, E. D., Yang, C., Thurberg, B. L., Kishnani, P. S., & Sun, B. (2017). Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy. Human gene therapy, 28(3), 286–294. https://doi.org/10.1089/hum.2016.099
Yi, H., Gao, F., Austin, S., Kishnani, P. S., & Sun, B. (2016). Alglucosidase alfa treatment alleviates liver disease in a mouse model of glycogen storage disease type IV. Molecular genetics and metabolism reports, 9, 31–33. https://doi.org/10.1016/j.ymgmr.2016.09.008
Yi, H., Zhang, Q., Yang, C., Kishnani, P. S., & Sun, B. (2016). A Modified Enzymatic Method for Measurement of Glycogen Content in Glycogen Storage Disease Type IV. JIMD reports, 30, 89–94. https://doi.org/10.1007/8904_2015_522
De Giorgi, M., Park, S. H., Castoreno, A., Cao, M., Hurley, A., Saxena, L., Chuecos, M. A., Walkey, C. J., Doerfler, A. M., Furgurson, M. N., Ljungberg, M. C., Patel, K. R., Hyde, S., Chickering, T., Lefebvre, S., Wassarman, K., Miller, P., Qin, J., Schlegel, M. K., Zlatev, I., … Lagor, W. R. (2025). In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene. Science translational medicine, 17(785), eadk3920. https://doi.org/10.1126/scitranslmed.adk3920
Chen, T., Barzi, M., Furey, N., Kim, H. R., Pankowicz, F. P., Legras, X., Elsea, S. H., Hurley, A. E., Yang, D., Wheeler, D. A., Borowiak, M., Bissig-Choisat, B., Sumazin, P., & Bissig, K. D. (2025). CRISPR/Cas9 gene therapy increases the risk of tumorigenesis in the mouse model of hereditary tyrosinemia type I. JHEP reports : innovation in hepatology, 7(4), 101327. https://doi.org/10.1016/j.jhepr.2025.101327
Barzi, M., Chen, T., Gonzalez, T. J., Pankowicz, F. P., Oh, S. H., Streff, H. L., Rosales, A., Ma, Y., Collias, S., Woodfield, S. E., Diehl, A. M., Vasudevan, S. A., Galvan, T. N., Goss, J., Gersbach, C. A., Bissig-Choisat, B., Asokan, A., & Bissig, K. D. (2024). A humanized mouse model for adeno-associated viral gene therapy. Nature communications, 15(1), 1955. https://doi.org/10.1038/s41467-024-46017-0
Ates, I., Stuart, C., Rathbone, T., Barzi, M., He, G., Major, A. M., Shankar, V., Lyman, R. A., Angner, S. S., Mackay, T. F. C., Srinivasan, S., Farris, A. B., Bissig, K. D., & Cottle, R. N. (2024). Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatology communications, 8(5), e0424. https://doi.org/10.1097/HC9.0000000000000424
Barzi, M., Johnson, C. G., Chen, T., Rodriguiz, R. M., Hemmingsen, M., Gonzalez, T. J., Rosales, A., Beasley, J., Peck, C. K., Ma, Y., Stiles, A. R., Wood, T. C., Maeso-Diaz, R., Diehl, A. M., Young, S. P., Everitt, J. I., Wetsel, W. C., Lagor, W. R., Bissig-Choisat, B., Asokan, A., … Bissig, K. D. (2023). Rescue of glutaric aciduria type I in mice by liver-directed therapies. Science translational medicine, 15(692), eadf4086. https://doi.org/10.1126/scitranslmed.adf4086
De Giorgi, M., Li, A., Hurley, A., Barzi, M., Doerfler, A. M., Cherayil, N. A., Smith, H. E., Brown, J. D., Lin, C. Y., Bissig, K. D., Bao, G., & Lagor, W. R. (2021). Targeting the Apoa1 locus for liver-directed gene therapy. Molecular therapy. Methods & clinical development, 21, 656–669. https://doi.org/10.1016/j.omtm.2021.04.011
Pankowicz, F. P., Barzi, M., Legras, X., Hubert, L., Mi, T., Tomolonis, J. A., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., Sumazin, P., Elsea, S. H., Bissig-Choisat, B., & Bissig, K. D. (2016). Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nature communications, 7, 12642. https://doi.org/10.1038/ncomms12642
Pendyal, S., Koch, R. L., Jones, H. N., & Kishnani, P. S. (2025). An Assessment of Dietary Intake, Feeding Practices, Growth, and Swallowing Function in Young Children with Late-Onset Pompe Disease: A Framework for Developing Nutrition Guidelines. Nutrients, 17(11), 1909. https://doi.org/10.3390/nu17111909
Koch, R. L., Kiely, B. T., Choi, S. J., Jeck, W. R., Flores, L. S., Sood, V., Alam, S., Porta, G., LaVecchio, K., Soler-Alfonso, C., & Kishnani, P. S. (2024). Natural history study of hepatic glycogen storage disease type IV and comparison to Gbe1ys/ys model. JCI insight, 9(12), e177722. https://doi.org/10.1172/jci.insight.177722
Beaman, M. M., Yin, W., Smith, A. J., Sears, P. R., Leigh, M. W., Ferkol, T. W., Kearney, B., Olivier, K. N., Kimple, A. J., Clarke, S., Huggins, E., Nading, E., Jung, S. H., Iyengar, A. K., Zou, X., Dang, H., Barrera, A., Majoros, W. H., Rehder, C. W., Reddy, T. E., … Crawford, G. E. (2025). Promoter Deletion Leading to Allele Specific Expression in a Genetically Unsolved Case of Primary Ciliary Dyskinesia. American journal of medical genetics. Part A, 197(2), e63880. https://doi.org/10.1002/ajmg.a.63880